An Overview of the Outset Medical Class Action Lawsuit
Levi & Korsinsky, LLP, a reputable law firm, is notifying investors about an important class action securities lawsuit involving Outset Medical, Inc. (NASDAQ: OM). This lawsuit has gained attention due to allegations of securities fraud impacting shareholders.
Understanding the Class Action Definition
This lawsuit aims to represent individuals who have faced losses from their investments in Outset Medical. It specifically targets the period from August 1, 2022 to August 7, 2024, during which the company allegedly engaged in misleading practices regarding its products.
Details of the Allegations
The allegations surrounding Outset Medical are significant. They indicate that the company may have made false statements regarding its Tablo products, which are crucial devices utilized in providing dialysis care. The essence of these claims revolves around several key points:
Key Misleading Statements
1. The Tablo products were incorrectly marketed as suitable for continuous renal replacement therapy, despite this indication not receiving FDA approval.
2. Outset Medical was expected to submit an additional 510(k) application for these products.
3. The sale of Tablo products could be halted pending FDA approval of new indications.
4. Outset Medical apparently lacked the required sales force and strategy to effectively boost Tablo sales.
5. These preceding factors were likely to hinder the company’s revenue growth.
6. Consequently, the defendants’ previous positive remarks regarding the company were misleading and lacked a credible basis.
The Road Ahead: Important Deadlines
For those who experienced financial losses related to their investments in Outset Medical, it is imperative to act quickly. Investors have until October 28, 2024 to file for lead plaintiff status, enabling them to seek a share of any financial recovery arising from the lawsuit.
No Upfront Costs
A significant aspect of this class action lawsuit is that affected investors can participate without incurring any out-of-pocket costs. This means that class members are entitled to potential compensation without the burden of upfront fees or costs.
Why Choose Levi & Korsinsky
Levi & Korsinsky boasts over two decades of experience in securities litigation, having successfully secured hundreds of millions of dollars for shareholders over the years. Their specialized expertise and a dedicated team of over 70 professionals position them as a strong advocate for investors navigating complex legal challenges.
Company Contact Information
For further inquiries regarding the lawsuit, investors should contact:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: jlevi@levikorsinsky.com
Phone: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com
Frequently Asked Questions
What is the purpose of this class action lawsuit?
The lawsuit seeks to recover financial losses for investors significantly affected by alleged securities fraud involving Outset Medical.
What are the main allegations against Outset Medical?
Outset Medical is accused of making false representations regarding their Tablo products, which could have misled investors about the company's financial health.
How can investors participate in the lawsuit?
Investors must act before the deadline of October 28, 2024, to file a request to be appointed as a lead plaintiff in the case.
Are there any costs to participate in the class action?
No, participants in the class action lawsuit are not required to pay any costs upfront.
Why is Levi & Korsinsky a reliable firm for this case?
With over 20 years of experience and a successful track record in securities litigation, the firm has proven itself as a trustworthy advocate for investors.
